High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction - PubMed

Abstract

The objectives of this study were to evaluate the efficacy and tolerability of high dose sildenafil as a salvage therapy for patients refractory to the maximum recommended dose of sildenafil. Fifty four fully evaluated patients with chronic erectile failure (ED) who had previously failed to respond to a home trial of sildenafil (100 mg) with erections suitable for sexual intercourse were studied. Each man was treated at home with sildenafil at escalating doses of up to 200 mg until either maximal response or intolerable adverse effects occurred. Erectile function was quantified using the erectile function domain of the International Index of Erectile Function (IIEF) before treatment, with sildenafil 100 mg and with maximal dose of sildenafil and a global efficacy question after 4 weeks of treatment. The mean age of the study group was 59.6+/-11.2 y. 13/54 (24%) had arteriogenic ED, 16/54 (30%) had mixed vasculogenic ED, 9/54 (17%) had cavernosal veno-occlusive dysfunction, 11/54 (20%) had post radical retropubic prostatectomy ED and 5/54 (9%) had psychogenic ED. 13/54 (24.1%) responded to sildenafil at a median maximal dose of 200 mg, 4/13 required 150 mg and 9/13 required 200 mg. 41/54 (76%) failed to respond to sildenafil. Mean IIEF question 3 and 4 scores were 1.5 and 1.4 at baseline, 2.2 and 1.9 with sildenafil 100 mg, 2.8 and 2.5 with sildenafil 150 mg and 3.0 and 2.9 with sildenafil 200 mg, respectively. After 4 weeks, treatment was regarded as having improved their erections by 37%, 46.3% and 68% of patients with sildenafil 100 mg, 150 mg and 200 mg, respectively. 34/54 (63%) reported adverse effects with maximal dose sildenafil comprising headache (19), facial flushing (32), dyspepsia (14), nasal congestion (11), dizziness (5) and visual disturbances (5). 4/13 (31%) responders refused to continue treatment due to adverse effects. In conclusion, sildenafil at doses of up to 200 mg is an effective salvage therapy for 24.1% of previous sildenafil non-responders but is limited by a significantly higher incidence of adverse effects and a 31% treatment discontinuation rate.

Comment in

• High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction.

  Seftel A. Seftel A. J Urol. 2003 Aug;170(2 Pt 1):684. J Urol. 2003. PMID: 14601583 No abstract available.

Similar articles

• Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction.

  McMahon CG, Samali R, Johnson H. McMahon CG, et al. J Urol. 2000 Oct;164(4):1192-6. J Urol. 2000. PMID: 10992364

• Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction.

  Buvat J, Hatzichristou D, Maggi M, Farmer I, Martínez-Jabaloyas JM, Miller PJ, Schnetzler G. Buvat J, et al. BJU Int. 2008 Dec;102(11):1645-50. doi: 10.1111/j.1464-410X.2008.07908.x. Epub 2008 Aug 14. BJU Int. 2008. PMID: 18710446 Clinical Trial.

• Prognostic factors predicting successful response to sildenafil after radical cystoprostatectomy.

  El-Bahnasawy MS, Ismail T, Elsobky E, Alzalouey EI, Bazeed MA. El-Bahnasawy MS, et al. Scand J Urol Nephrol. 2008;42(2):110-5. doi: 10.1080/00365590701571563. Scand J Urol Nephrol. 2008. PMID: 17853038 Clinical Trial.

• Erection hardness: a unifying factor for defining response in the treatment of erectile dysfunction.

  Mulhall JP, Levine LA, Jünemann KP. Mulhall JP, et al. Urology. 2006 Sep;68(3 Suppl):17-25. doi: 10.1016/j.urology.2006.05.041. Urology. 2006. PMID: 17011372 Review.

Cited by

• Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.

  Frajese GV, Pozzi F, Frajese G. Frajese GV, et al. Clin Interv Aging. 2006;1(4):439-49. doi: 10.2147/ciia.2006.1.4.439. Clin Interv Aging. 2006. PMID: 18046921 Free PMC article. Review.

• Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil.

  Raheem AA, Kell P. Raheem AA, et al. Patient Prefer Adherence. 2009 Nov 3;3:99-104. doi: 10.2147/ppa.s3349. Patient Prefer Adherence. 2009. PMID: 19936151 Free PMC article.

• Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.

  Hatzimouratidis K. Hatzimouratidis K. Clin Interv Aging. 2006;1(4):403-14. doi: 10.2147/ciia.2006.1.4.403. Clin Interv Aging. 2006. PMID: 18046917 Free PMC article. Review.

• Treating erectile dysfunction when PDE5 inhibitors fail.

  McMahon CN, Smith CJ, Shabsigh R. McMahon CN, et al. BMJ. 2006 Mar 11;332(7541):589-92. doi: 10.1136/bmj.332.7541.589. BMJ. 2006. PMID: 16528082 Free PMC article. Review. No abstract available.

• Drug-related problems in patients with erectile dysfunctions and multiple comorbidities.

  Huri HZ, Ling CF, Razack AH. Huri HZ, et al. Ther Clin Risk Manag. 2017 Mar 31;13:407-419. doi: 10.2147/TCRM.S118010. eCollection 2017. Ther Clin Risk Manag. 2017. PMID: 28408836 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Medical

  • MedlinePlus Health Information